InvestorsHub Logo
Post# of 252204
Next 10
Followers 6
Posts 703
Boards Moderated 0
Alias Born 09/23/2006

Re: DewDiligence post# 235314

Thursday, 10/29/2020 11:26:26 AM

Thursday, October 29, 2020 11:26:26 AM

Post# of 252204
ABBV phase-3 trials in presbyopia hit primary endpoint

Interesting, might be why EYEN is pushing harder on the Myopia trial and partnering with Bausch and Lomb for this application.

"Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12"

https://www.prnewswire.com/news-releases/bausch-health-licenses-eyenovias-investigational-treatment-for-the-reduction-of-pediatric-myopia-progression-in-children-ages-3-12-301149863.html

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.